BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Semaglutide (Wegovy tablets) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Semaglutide (Wegovy tablets)\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07225816-11055@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20261213
DTEND;VALUE=DATE:20261214
SUMMARY:Semaglutide (Wegovy tablets): Phase 1 readout est. (NCT07225816)
DESCRIPTION:Semaglutide (Wegovy tablets)\, phase 1\, Obesity.\nStudy: Exami
 nation of How the Duration of Fasting and Temporary Stopping of GLP-1 Medi
 cations Affect the Amount of Food Left in the Stomach in People Using Lira
 glutide (Injected)\, Semaglutide (Taken by Mouth) or Semaglutide (Injected
 )\nEstimated primary completion: 13 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07225816
URL:https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770841-11055@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:Semaglutide (Wegovy tablets): Phase 3 readout est. (NCT07770841)
DESCRIPTION:Semaglutide (Wegovy tablets)\, phase 3\, Obesity.\nStudy: Resea
 rch Study on How Well Oral Semaglutide Works for Weight Loss in Adults Wit
 h Excess Body Weight\nEstimated primary completion: 22 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/semaglutide-wegovy-tablet
 s#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 770841
URL:https://assetmemo.bio/drug/semaglutide-wegovy-tablets#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
